(c) (f) and (g) Prices of finished vaccines are controlled under the DPCO. Details will be comuiled and laid on the table of the House. The DPCO has moderated the prices of vaccines.

(d) and (e) Information to the extent available is given in the Annexure.

**Annexure**

*I Production*

| Year | Production | |
|---|---|---|
| | Anti Gas Gengrene vaccine (Ltrs.) | Anti Rabbies Vaccine (K. Ltrs.) |
| 1982-83 | 14.00 | 5.95 |
| 1983-84 | 29.00 | 6.37 |
| 1984-85 | 5.00 | 5.30 |

*II Imports*

| Item | Import (Doses) | | |
|---|---|---|---|
| | 1982-83 | 1983-84 | 1984-85 |
| 1. Poliomyelitis vaccine (Inactivated) | Nil | 20,000 | Nil |
| 2. Poliomyelitis Vaccine Trivalent (Oral) | 3066000 | 160750 | 7252280 |
| 3. Poliomyelitis Vaccine (Monovalent) | 41000000 | 35000000 | 52500000 |

**Production of Drugs**

840. SHRIMATI MAIMOONA SULTAN: Will the Minister of INDUSTRY be pleased to state:

(a) names of the drugs under category I and II of existing Drugs Price Control Order 1979 for which production has fallen from the inception of Price Control Order, 1979.

(b) what was the production of each of these drugs during 1978 and 1985 and what is the percentage of fall in each case;

(c) names of the producers who are licensed to produce these drugs alongwith name, licenced and installed capacity and production of each drug during the last three years, year-wise; and

(d) names of formulations and drugs which fall under exempted category being produced by these companies and what was the production of Bulk Drugs and sales turn-over of formulations during 1978 and 1985 separately?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) Among the monitored category I and II bulk drugs the production of Dapsone, Di-iodohydroxyquinoline, Iodochlorohydroxy quinoline, PAS and its Salts, Penicillin, Amodiaquin, Analgin, Phenobarbitone and Sulphadimidine was

lower in 198485, in 1984-85, in comparison with 1979-80.

(b) and (c) Details to the extent available, are given in Annexure I and II.

(d) Sales turn-over of formulations is not monitored. Other detail to the extent available, will be collected and laid on the table of the House.

**Annexure—I**

| Sl. No. | Name of the Drug | A/C Unit | Production 1978-79 | Production 1984-85 | Percentage variation in production |
|---|---|---|---|---|---|
| 1 | Dapsone | T | 18.05 | 7.25 | (—) 59.8 |
| 2 | Di-iodohydroxy Quinoline | T | 9.91 | 3.22 | (—) 67.5 |
| 3 | Idochlorohydroxy Quinoline | T | 142.68 | 151.10 | (+) 5.9 |
| 4 | PAS & Its Salts | T | 601.46 | 119.07 | (—) 80.2 |
| 5 | Penicillin | MNU | 319.95 | 221.68 | (—) 30.7 |
| 6 | Amodiaquin | T | 29.00 | 26.41 | (—) 26.9 |
| 7 | Analgin | T | 277.79 | 335.87 | (+) 20.9 |
| 8 | Phenobarbitone | T | 20.53 | 5.09 | (—) 75.2 |
| 9 | Sulphadimidine | T | 375.18 | 313.60 | (—) 16.4 |

**Annexure—II**

| Name of drug/Manufacturing Unit | A/c Unit | Licensed Capacity | Production 1982-83 | Production 1983-84 | Production 1984-85 |
|---|---|---|---|---|---|
| *I. Dapsone* | T | | | | |
| (i) B.C.P.L. | | 15.00 | 7.58 | 6.05 | 2.75 |
| (ii) Burroughs-Wellcome | | 28.00 | 23.36 | 22.92 | 4.43 |
| (iii) Tuber Pharma | | | | 0.80 | 0.07 |
| *II. Di-Iodohydroxy Quinoline* | T | | | | |
| (i) Albert David | | $ | 4.17 | 4.63 | 3.22 |
| *III. Iodochlorohydroxy Quinoline* | T | | | | |
| (i) Albert David | | 4.25 | 6.18 | 5.84 | 11.47 |
| (ii) Amul | | 170.00 | 140.40 | 54.78 | 69.28 |
| (iii) E.I.P.W. | | 212.00 | 52.42 | 57.15 | 65.91 |
| (iv) Bio-Evans | | 12.00 | | | 4.44 |

| 1 | 2 | 3 | 4 | 5 | 6 | |
|---|---|---|---|---|---|---|
| *IV. Pas and ITS Salts* | | T | | | | |
| (i) | I.D.P.L. | | 400.00 | 102.30 | 114.55 | 29.15 |
| (ii) | Biochem Synth | | 100.00 | 104.40 | 77.31 | 76.15 |
| (iii) | Pfizer | | 110.00 | 12.60 | 3.67 | 8.52 |
| (iv) | Wander | | 300.00 | 26.60 | 21.46 | 5.25 |
| *V. Penicillin* | | MMU | | | | |
| (i) | I.D.P.L. | | 230.00 | 58.52 | 55.60 | 31.20 |
| (ii) | H.A.L. | | 160.00 | 72.21 | 69.02 | 69.94 |
| (iii) | Alembic | | 100.00 | 101.19 | 84.60 | 52.53 |
| (iv) | Standard Pharma | | 147.00 | 126.45 | 107.52 | 65.01 |
| *VI. Amodiaquin* | | T | | | | |
| (i) | Parke-Davis | | 36.00 | 20.53 | 7.86 | 5.12 |
| (ii) | Suncota Chem. | | 30.00 | 9.62 | 15.55 | 21.29 |
| *VII. Analgin* | | T | | | | |
| (i) | I.D.P.L. | | 400.00 | 239.20 | 314.71 | 335.87 |
| *VIII. Phenobarbitone* | | T | | | | |
| (i) | I.D.P.L. | | 30.00 | 29.40 | 12.86 | 5.09 |
| *IX. Sulphadimidine* | | T | | | | |
| (i) | I.D.P.L. | | 1000.00 | 513.25 | 480.60 | 313.60 |

$ : Combined Capacity with Iodo-Chlorohydroxyquinoline.

**Production of Steriods**

841. SHRIMATI MAIMOONA SULTAN: Will the Minister of INDUSTRY be pleased to state:

(a) names of the companies which are licenced to produce steriods and cartico-steriods from basic stages alongwith the name of each drug falling under this category;

(b) whether it is a fact that these companies, instead of producing from basic stages are producing from imported and locally procured imported penultimates/intermediates;

(c) what is the quantity of each imported penultimate and intermediat procured locally and imported by each manufacturer during the last three years, year-wise.

(d) whether it is a fact that on the one side the capacities are lying idle for production of intermediates|penultimates and on other side huge foreign exchange is being wasted; and

(e) what are the reasons for not monitoring such imports by the Department?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) M|s. Glaxo and M|s. Wyeth are licensed to